新加坡的Biosyngen获得FDA批准,用于EBV特异性CAR-T细胞治疗BRG01的II期试验,标志着固体瘤治疗的重要里程碑. Singapore's Biosyngen receives FDA approval for Phase II trial of EBV-specific CAR-T cell therapy BRG01, marking a significant milestone in solid tumor treatments.

新加坡的Biosyngen获得FDA批准,用于EBV特异性CAR-T细胞治疗BRG01的II期试验,使其成为美国和中国的第一个用于治疗复发/转移EBV阳性鼻癌的细胞治疗. Singapore's Biosyngen receives FDA approval for Phase II trial of EBV-specific CAR-T cell therapy BRG01, making it the first cell therapy in both US and China for treating relapsed/metastatic EBV-positive nasopharyngeal carcinoma. 这标志着固态肿瘤治疗方面的一个重要里程碑。 This marks a significant milestone in solid tumor treatments. 生物合成物旨在加速BRG01为全世界鼻喉癌患者的发展。 Biosyngen aims to accelerate BRG01's development for nasopharyngeal cancer patients worldwide.